“Genetic medicine” is a new type of biopharmaceutical that utilizes the gene functions. Speed Realize innovative gene medicines to ensure prompt delivery to patients in need.Īs a biotech venture company, we focus on research and development of the next-generation biopharmaceuticals such as genetic medicines, and aim to achieve practical use of innovative drugs. Ethics Work with the highest ethical standards. Genesis Continue to incorporate latest research results and ideas, and strive to create new technologies, products and value. Patients, shareholders, alliance partners, employees and local communities are vital partners forming the foundation of its networks. Network AnGes believes that every network is a key to creating new value. We respectfully ask for your continued support moving forward.Ĭontribute to the improvement of human health and quality of life through the development of innovative medicines, by harnessing the potential of genes, acquired over the long course of the humankind.Īchieve the Corporate Mission by acting along the principles incorporated in the company name “A-N-G-E-S”: Aspiration Recognize and value the importance of the networks consisting of patients, medical professionals, shareholders, alliance partners, employees and local communities. Thank you very much for your ongoing support and encouragement. We will continue striving to be a global leader in genetic medicine, and by using our genetic medicine technologies we intend to live up to the expectations of patients hoping for new drugs and their families, other stakeholders and wider society. Even so the actual number of hard-to-treat diseases and rare diseases around the world is said to run into thousands. Around the world, the drug discovery domain like other domains is seeing the introduction of AI technology and DX (digital transformation) in health care, and there are more possibilities of development ideas than before, with less time required for development. We would like to make our products available to such patients all around the world.Īnother challenge we face is achieving the long-standing goal of therapeutic drugs for hard-to-treat and rare diseases. There are far more patients suffering with ischemic heart disease overseas than in Japan. At the same time, we feel an enormous sense of responsibility to deliver our products to patients suffering overseas. The experience of launching our own products for the first time as a Japanese bio-venture filled us with enormous confidence and even greater courage. The success probability in new drug development is said to be 1/25,000. For 20 years we experienced challenges and setbacks and then in September 2019, we obtained approval for the world's first gene therapy product that can help regenerate blood vessels and, with its inclusion in the NHI price list, began marketing it as the world's first gene therapy product using plasmid DNA technology. Both our founder and our employees are still motivated by this desire.Īt the time of our foundation, therapeutic angiogenesis was still a new therapeutic approach. Originating from the word angiogenesis meaning the formation of new blood vessels in English, our corporate name AnGes encapsulates our desire to be an angel (ange in French) offering new drugs for patients with hard-to-treat and rare diseases. AnGes was founded In December 1999, with the aim of developing hepatocyte growth factor (HGF) gene therapy drugs which can help regenerate blood vessels.
0 Comments
Leave a Reply. |